Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2017-02-28 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated February 28, 2017, announcing two key achievements for Theraclion in Germany: winning a Stevie Award and securing improved reimbursement coverage for its Echopulse device from the German insurer BKK VBU. This type of announcement, detailing positive business developments, awards, and market access achievements, is characteristic of a general corporate announcement or press release. It is not a formal regulatory filing like a 10-K, a detailed financial report (IR/MRQ), a transcript (CT), or a specific shareholder document (DEF 14A/DVA). Since it is a general announcement of positive news that doesn't fit the highly specific categories (like M&A, Dividend, Director Dealing), the most appropriate classification is the general Regulatory Filings category (RNS), which often serves as a catch-all for press releases that aren't explicitly covered elsewhere, especially when they relate to market access and awards.
2017-02-28 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Legal Proceedings Report Classification · 99% confidence The document is a press release from Theraclion announcing that the first patients have been treated in a pivotal multicentre FDA study for their Echopulse® device. It details the trial scope, investigators, and the significance of the development for the U.S. market. This type of announcement, focusing on clinical trial progress, regulatory milestones, or significant operational updates that are not standard financial reports (like 10-K, ER, or IR), typically falls under general regulatory announcements or investor relations news. Since it is not a formal financial report, a management change, a dividend notice, or a specific legal filing, the most appropriate general category for significant, non-financial operational news is Regulatory Filings (RNS), which serves as a broad category for important company announcements not covered elsewhere. Given the short length and announcement nature, it is not a comprehensive report like an IR or 10-K.
2017-02-08 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated February 8, 2017, announcing that Theraclion has begun treating the first patients in the US for a pivotal FDA study regarding their Echopulse® therapy for breast fibroadenomas. It details the study scope, participating centers, and includes quotes from the principal investigator and the CEO. This type of announcement, focusing on clinical trial progress and market potential, is a general corporate update. It is not a formal regulatory filing (like 10-K or IR), a financial results release (ER), or a management change announcement (MANG). Since it is a specific operational/clinical update that doesn't fit the highly specific categories like DIV, CAP, or DIRS, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant corporate news not covered elsewhere, or potentially 'LTR' if viewed as a regulatory milestone announcement, but RNS is the most appropriate general catch-all for press releases detailing operational progress.
2017-02-08 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 95% confidence The document is a press release dated January 09, 2017, announcing business developments for Theraclion, specifically regarding insurance coverage expansion and new commercial agreements for its Echopulse® system in Germany. It details market traction, new installations, and mentions upcoming clinical trials. This type of announcement, focusing on business progress, market access, and sales achievements, is characteristic of an Earnings Release (ER) or a general business update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede formal quarterly/annual reporting periods to highlight key operational successes. It is not an RPA because it is the substantive announcement itself, not just a notice that a report is available. It is not an MDA because it lacks the detailed management discussion and analysis of financial statements typically found in that category; it is focused on commercial milestones. FY 2017
2017-01-09 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated January 9, 2017, announcing business developments for Theraclion, specifically regarding the reimbursement of its Echopulse® therapy by a major German insurance company and two new commercial agreements in Frankfurt. This type of announcement, detailing business progress, market expansion, and commercial milestones, is characteristic of a general corporate update or press release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is a general announcement of business progress and market traction, and does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous official announcements that aren't covered by more specific codes. Given the content is a news announcement rather than a formal financial report, RNS is the most appropriate fit among the provided options.
2017-01-09 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated January 4, 2017, from THERACLION announcing an agreement with a hospital (Pitié-Salpêtrière) to offer echotherapy for thyroid nodules and noting the publication of new medical guidelines supporting this treatment. This type of announcement, detailing a business development, partnership, or significant operational update that is not a mandatory periodic financial filing (like 10-K or IR) or a specific event report (like AGM or DIV), typically falls under general regulatory announcements or news releases. Since it is a specific announcement of a business/medical development and not a general regulatory filing fallback (RNS), and it doesn't fit any other specific category (like ER, CT, CAP, etc.), it is best classified as a general Regulatory Filing (RNS) as it is a formal communication to the market about a material event, or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a formal report, which it is not doing directly, but rather announcing the adoption of guidelines. Given the context of a press release announcing a clinical/business milestone, RNS is the most appropriate general category for non-standard, material news.
2017-01-04 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.